<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27438211</article-id>
      <article-id pub-id-type="pmc">4938288</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20163960</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Ulcerations due to methotrexate toxicity in a psoriasis patient<xref ref-type="fn" rid="fn1">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Souza</surname>
            <given-names>Claudia Fernanda Dias</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suarez</surname>
            <given-names>Olga Milena Zarco</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>da Silva</surname>
            <given-names>Talita Fonseca Medeiros</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gorenstein</surname>
            <given-names>Ana Carolina Louren&#xE7;o Ara&#xFA;jo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Quintella</surname>
            <given-names>Leonardo Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Avelleira</surname>
            <given-names>Jo&#xE3;o Carlos Regazzi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Instituto de Dermatologia Professor Rubem David Azulay
da Santa Casa da Miseric&#xF3;rdia do Rio de Janeiro (IDPRDA/SCMRJ) - Rio de
Janeiro (RJ), Brazil.</aff>
      <aff id="aff2"><label>2</label>Funda&#xE7;&#xE3;o Oswaldo Cruz (FIOCRUZ) - Rio de
Janeiro (RJ), Brazil. </aff>
      <author-notes>
        <corresp id="c1">Mailing address: Claudia Fernanda Dias Souza, R. Santa Luzia, 206,
Centro, 20020-020 - Rio de Janeiro - RJ, Brazi, E-mail:
<email>cfdsouza.rj@gmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2016</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2016</year>
      </pub-date>
      <volume>91</volume>
      <issue>3</issue>
      <fpage>375</fpage>
      <lpage>377</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>8</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2016 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Methotrexate is one of the most used drugs in the treatment of psoriasis with
indication of systemic therapy. Cutaneous and mucous side effects are described
by pharmacological characteristics of the drug itself or due to overdose. We
report the case of a patient with ulcerations in oral mucosa and psoriatic
plaques after incorrect use of Methotrexate. Prescribed in a weekly dose, it was
used continuously for 10 days and without simultaneous intake of folic acid. It
is important to ensure correct comprehension of the prescription.</p>
      </abstract>
      <kwd-group>
        <kwd>Methotrexate</kwd>
        <kwd>Psoriasis</kwd>
        <kwd>Therapeutics</kwd>
        <kwd>Toxicity</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Methotrexate (MTX) was introduced as antipsoriatic agent in 1951 and approved by FDA
(<italic>Food and Drug Administration</italic>) with this indication in 1972.
Structurally similar to folic acid, MTX is irreversibly linked to dihydrofolate
reductase, exerting antiproliferative activity. It induces apoptosis and increases
the concentration of adenosine, resulting also in anti-inflammatory and
immunoregulation action.<sup><xref rid="r1" ref-type="bibr">1</xref></sup></p>
      <p>Psoriasis is a frequent dermatosis that may progress to severe forms that require
systemic medication.<sup><xref rid="r2" ref-type="bibr">2</xref></sup> In these
cases, MTX is one of the most used drugs, due to its efficiency, safety (in
prescribed doses) and low cost. However, overdose of MTX may cause important
cutaneous, oral mucosa and systemic side effects.</p>
      <p>The most common skin/mucosa alterations related to its toxicity are ulcerations on
the oral mucosa, while reports of such alterations in preexisting psoriatic lesions
or even on healthy skin are rare.<sup><xref rid="r3" ref-type="bibr">3</xref></sup></p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A female patient, 58 years old, of mixed race, diagnosed with psoriasis 3 years
before presented generalized lesions in the form of plaques and with poor response
to topical treatment. The PASI (<italic>Psoriasis Area Severity Index</italic>) test
had a result of 10.6. MTX was prescribed in a weekly dose of 10 mg orally,
accompanied by 5 mg of folic acid 3 times a week. Ten days later she returned with
intense dysphagia for solids and liquids, diarrhea and myalgia. She was dysphonic,
with multiple erosions on the oral mucosa, hard and soft palate and ulcerations
located mainly on the periphery of preexisting plaque psoriasis (<xref ref-type="fig" rid="f1">Figures 1</xref>, <xref ref-type="fig" rid="f2">2</xref>
and <xref ref-type="fig" rid="f3">3</xref>). The histopathological examination
revealed an ulcerated area covered by regenerating exudate and epithelium, ectasia
in proliferated vessels and neutrophils at the bottom of the lesion (<xref ref-type="fig" rid="f4">Figure 4</xref>). After denying irregular use of
medication at first, the patient then admitted having ingested 10 mg of MTX daily
and that she had not used folic acid as originally recommended. She was hospitalized
for evaluation of possible hematological and hepatic alterations and started
receiving folinic acid 25mg/day intravenously.</p>
      <p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Ulcerated lesion on oral mu cosa</p></caption><graphic xlink:href="abd-91-03-0375-g01"/></fig>
</p>
      <p>
<fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Ulcerated areas in the a periphery of psoriatic plaques on upper
limbs</p></caption><graphic xlink:href="abd-91-03-0375-g02"/></fig>
</p>
      <p>
<fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>In closer de tail, on left knee</p></caption><graphic xlink:href="abd-91-03-0375-g03"/></fig>
</p>
      <p>
<fig id="f4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Histopathology: Ulcerated area covered by exudate and regenerating
epithelium. Proliferating vessels and neutrophils</p></caption><graphic xlink:href="abd-91-03-0375-g04"/></fig>
</p>
      <p>The laboratory tests revealed leukopenia (2.780 mil/mm<sup>3</sup>) with
hypersegmentation of neutrophils, decrease in total red blood cells, hematocrits and
hemoglobin (3.860.000 u/l, HT: 31.7%, Hb: 10g/dl) with absence of alterations in
liver and kidney function. The patient progressed with rapid improvement and was
discharged on the 8<sup>th</sup> day of hospitalization. Thirty days later,
follow-up showed complete reepithelization of lesions. The tests demonstrated
normalization of leukocytes (8.600 mil/mm<sup>3</sup>) and slower recuperation of
the red series (HT: 31.9%, Hb: 10.1g/dl). After being oriented again, the patient
continued to use MTX, keeping the disease under control (PASI: 2.4) for 18 months of
follow-up.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Methotrexate is a relatively safe drug in the dosage used in dermatology (7.5 mg to
25 mg/week), with side effects and toxicity associated with idiosyncratic or
dose-dependent mechanisms. The latter will occur mainly in cells that proliferate
faster, like hematopoietic bone marrow cells, epithelial gastrointestinal tube and
epidermal cells. As MTX is excreted by the kidneys and circulates in the blood flow
conjugated with albumin, its administration to nephropathic patients or those with
hypoalbuminemia should be done carefully or avoided. Furthermore, drug interaction
(drugs that diminish renal excretion of MTX, that inhibit folate synthesis, or that
decrease MTX binding to proteins) and errors in administration of the drug may
trigger adverse effects through the increased drug level in the body.</p>
      <p>On the skin, the adverse affects are more rare. Not related to the methotrexate dose
have been described: erythematous eruptions, blisters, toxic epidermal necrolysis,
exacerbation of photosensitivity reactions, purpuric lesions due to vasculitis,
hives and formation of nodules that may involve internal organs also, first reported
in rheumatoid arthritis and later found in psoriasis and psoriatic
arthritis.<sup><xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r6" ref-type="bibr">6</xref></sup></p>
      <p>Cutaneous manifestations in patients with MTX dose-dependent psoriasis are more
frequent due to acute intoxication. Ulcerations and ulcerative processes are
observed on oral mucosa (more precocious), on psoriatic plaques, in other
preexisting dermatoses or, more rarely, on healthy skin.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> They may be similar to a "flare-up" of psoriasis or
to pustular psoriasis.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref></sup></p>
      <p>Pearce and Wilson<sup><xref rid="r6" ref-type="bibr">6</xref></sup> reviewed 47 cases
in the period of 1951 to 1996 and found simultaneous use of non-hormonal
anti-inflammatories and advanced age as risk factors. Many of these cases occurred
in the first weeks after introduction of MTX or reintroduction of medication in
patients with relapsing disease, suggesting the hypothesis of higher susceptibility
to MTX of phase S cells, that are found in larger numbers when there is acceleration
of the epidermal turn over.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r8" ref-type="bibr">8</xref></sup></p>
      <p>The histopathological study of eroded cutaneous lesions shows a microscopic image
similar to that observed after intradermal administration of the drug, suggesting
that the reaction is caused by a direct cytotoxic effect.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> Therefore, the alterations observed would be derived
from inhibition of keratinocytes by direct MTX toxicity, leading to epidermal
necrosis.</p>
      <p>In case of acute intoxication by MTX, skin signs and symptoms are a toxicity alert
sign and may precede more serious hematologic alterations. The treatment is made
with immediate suspension of the drug and administration of parenteral folinic acid
in the dose of 10 mg/m<sup>2</sup> of body surface; the earlier the treatment, the
higher the success rate, mainly regarding the attempt to avoid or interrupt
myelosuppressive effects.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> As
regards skin lesions, reepithelization takes place between 1 and 2 weeks after
interruption of medication and beginning of the new treatment.<sup><xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>Methotrexate is an option of great therapeutic value for psoriasis, and its use
should be well guided by the physician. The patient should be totally aware of the
risks and side effects. More safety is achieved by means of a rigorous selection of
patients (considering absolute and relative contraindications) and periodical
clinical-laboratorial follow-up. In case of elderly patients or those with cognitive
difficulties it is of fundamental importance for a companion to be present to ensure
more safety to the offered treatment.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Work carried out at the Instituto de Dermatologia Professor Rubem David Azulay da
Santa Casa da Miseric&#xF3;rdia do Rio de Janeiro (IDPRDA/SCMRJ) - Rio de Janeiro
(RJ), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Alencar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Avelleira</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <chapter-title>Metotrexate</chapter-title>
          <source>Consenso Brasileiro de Psor&#xED;ase 2012: guias de
avalia&#xE7;&#xE3;o e tratamento Sociedade Brasileira de
Dermatologia</source>
          <edition>2 ed</edition>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
          <year>2012</year>
          <fpage>67p</fpage>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ata&#xED;de</surname>
              <given-names>DST</given-names>
            </name>
            <name>
              <surname>Esmanhoto</surname>
              <given-names>LDK</given-names>
            </name>
            <name>
              <surname>Helmer</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Guerra</surname>
              <given-names>IRC</given-names>
            </name>
            <name>
              <surname>Guimar&#xE3;esn</surname>
              <given-names>CCG</given-names>
            </name>
            <name>
              <surname>Moritz</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Ulcera&#xE7;&#xE3;o das placas psori&#xE1;ticas - efeito
adverso do metotrexate em altas doses no tratamento da psor&#xED;ase:
relato de tr&#xEA;s casos</article-title>
          <source>An Bras Dermatol</source>
          <year>2003</year>
          <volume>78</volume>
          <fpage>749</fpage>
          <lpage>753</lpage>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerstens</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Boerbooms</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Jeurissen</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Fast</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Assmann</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>van de Putte</surname>
              <given-names>LB</given-names>
            </name>
          </person-group>
          <article-title>Accelerated nodulosis during low dose methotrexate therapy for
rheumatoid arthritis. An analysis of ten cases</article-title>
          <source>J Rheumatol</source>
          <year>1992</year>
          <volume>19</volume>
          <fpage>867</fpage>
          <lpage>871</lpage>
          <pub-id pub-id-type="pmid">1404122</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lebwohl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ting</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Koo</surname>
              <given-names>JYM</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis treatment: traditional therapy</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <fpage>ii83</fpage>
          <lpage>ii86</lpage>
          <pub-id pub-id-type="pmid">15708945</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Seo</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sung</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title>A Case of Cutaneous Side Effect of Methotrexate Mimicking
Beh&#xE7;et's Disease</article-title>
          <source>Ann Dermatol</source>
          <year>2011</year>
          <volume>23</volume>
          <fpage>412</fpage>
          <lpage>414</lpage>
          <pub-id pub-id-type="pmid">21909222</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pearce</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>BB</given-names>
            </name>
          </person-group>
          <article-title>Erosion of psoriatic plaques: An early sign of methotrexate
toxicity</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1996</year>
          <volume>35</volume>
          <fpage>835</fpage>
          <lpage>838</lpage>
          <pub-id pub-id-type="pmid">8912599</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>KishanKumar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>AmiyaKumar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>DevinderMohan</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Methotrexate toxicity presenting as ulceration of psoriatic
plaques: A report of two cases</article-title>
          <source>Indian J Dermatol Venereol Leprol</source>
          <year>2008</year>
          <volume>74</volume>
          <fpage>481</fpage>
          <lpage>484</lpage>
          <pub-id pub-id-type="pmid">19052409</pub-id>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Truchuelo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Alc&#xE1;ntara</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vano-Galv&#xE1;n</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ja&#xE9;n</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Focal skin toxicity related to methotrexate sparing psoriatic
plaques</article-title>
          <source>Dermatol Online J</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>16</fpage>
          <pub-id pub-id-type="pmid">20579471</pub-id>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xF3;pez</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Toxicidad aguda por metotrexate en psoriasis</article-title>
          <source>Gac M&#xE9;d M&#xE9;x</source>
          <year>1999</year>
          <volume>135</volume>
          <fpage>513</fpage>
          <lpage>516</lpage>
          <pub-id pub-id-type="pmid">10596492</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fridlington</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Tripple</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Reichenberg</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Diven</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Acute methotrexate toxicity seen as plaque psoriasis ulceration
and necrosis: A diagnostic clue</article-title>
          <source>Dermatol Online J</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>2</fpage>
          <pub-id pub-id-type="pmid">22136858</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
